Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2017-08-28 Governance Information
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Appendix 4G and Corporate Governance Statement 23 pages 715.5KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures required to be lodged with the ASX alongside the annual report. The content is a detailed key to disclosures against the ASX Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2017. It includes statements about the corporate governance statement being available on the company's website and approved by the board. The document is focused on governance practices and compliance with governance recommendations rather than financial results or management changes. It is not the annual report itself but a regulatory filing related to governance disclosures required by the ASX. The document length (15,000 characters) and detailed governance content indicate it is not a brief announcement but a formal governance disclosure. Therefore, the most appropriate classification is Governance Information (CGR).
2017-08-28 English
Preliminary Final Report and Financial Statements 45 pages 1.5MB
Annual Report Classification · 100% confidence The document is titled 'Preliminary Final Report 30 June 2017' and references the Appendix 4E, which is a regulatory filing related to the full-year financial results. It includes detailed financial results, directors' report, consolidated financial statements, and an independent auditor's report for the year ended 30 June 2017. The document contains comprehensive financial data and analysis for the full fiscal year, including profit/loss, revenue, cash flow, and notes to the financial statements. It also includes the directors' report and audit report, which are typical components of an Annual Report. The length of the document (15,000 characters) and the presence of full financial statements confirm it is the actual report, not just an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2017
2017-08-22 English
Living Insights Newsletter July 2017 2 pages 552.1KB
Regulatory Filings Classification · 85% confidence The document is titled 'Living Insights' and is described as an occasional publication providing up-to-date information about Living Cell Technologies. It includes a message from the CEO, updates on clinical trials (Phase IIb and Phase I/IIa) of their product NTCELL for Parkinson's disease, research collaborations, and general company news. There are no detailed financial statements, regulatory filings, or formal report structures typical of annual or interim reports. The content is more of an informational newsletter or update rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Regulatory Filings (RNS). It is also not a presentation, call transcript, or governance document. Given the nature of the content as a company newsletter providing updates on research and corporate news, the best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous company updates that do not fit other categories.
2017-07-23 English
Appendix 4C - quarterly 7 pages 794.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 30 June 2017' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as cash balances and estimated cash outflows for the next quarter. The report is prepared in accordance with Listing Rule 4.7B, which mandates quarterly reporting of cash flows for entities listed on the ASX. The content is a comprehensive quarterly financial report with actual financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not a mere announcement or certification but contains substantive financial data and analysis. Q4 2017
2017-07-19 English
Appendix 3B 9 pages 679.6KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares by Living Cell Technologies Limited. It includes specifics such as the number of securities issued, issue price, terms, and compliance with ASX listing rules. The document is a formal announcement related to the issuance and quotation of additional securities on the ASX. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is clearly an announcement of a capital raising event through new share issuance. Therefore, the document fits the category of 'Capital/Financing Update' (CAP). The document length is over 11,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2017-06-29 English
Cleansing Statement 1 page 301.2KB
Capital/Financing Update Classification · 95% confidence The document is a short notice from Living Cell Technologies Limited regarding the issuance of shares due to the exercise of employee options. It references compliance with sections of the Corporations Act and provides a formal notice under Section 708A. The content is a regulatory announcement about share issuance without disclosure under certain provisions, not a full financial report or detailed financial data. The document length is only 1135 characters, indicating it is a brief announcement rather than a comprehensive report. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share issuance.
2017-06-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.